View Older Stories View More Recent Stories

Mar 29, 2023 07:00AM Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
Mar 29, 2023 07:00AM Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
Mar 6, 2023 07:00AM Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 6, 2023 07:00AM Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 27, 2023 07:00AM Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
Feb 27, 2023 07:00AM Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
Feb 9, 2023 07:00AM Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Feb 9, 2023 07:00AM Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Jan 9, 2023 07:00AM Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
Jan 9, 2023 07:00AM Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
Dec 19, 2022 04:30PM Entrada Therapeutics (TRDA) Announces Clinical Hold on IND Application for ENTR-601-44
Dec 19, 2022 04:30PM Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
Dec 19, 2022 04:30PM Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
Dec 8, 2022 07:01AM Vertex Pharma (VRTX) , Entrada Therapeutics (TRDA) Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1
Dec 8, 2022 07:00AM Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Nov 22, 2022 07:00AM Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
Nov 22, 2022 07:00AM Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
Nov 7, 2022 07:00AM Entrada Therapeutics Reports Third Quarter 2022 Financial Results
Nov 7, 2022 07:00AM Entrada Therapeutics Reports Third Quarter 2022 Financial Results
Aug 30, 2022 07:00AM Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 30, 2022 07:00AM Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 11, 2022 07:00AM Entrada Therapeutics Reports Second Quarter 2022 Financial Results
Aug 11, 2022 07:00AM Entrada Therapeutics Reports Second Quarter 2022 Financial Results
Aug 4, 2022 07:05AM Entrada Therapeutics (TRDA) Collaborates with Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
Aug 4, 2022 07:00AM Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
Aug 4, 2022 07:00AM Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
Jul 19, 2022 07:00AM Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
Jul 19, 2022 07:00AM Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
Jul 6, 2022 07:00AM Entrada Therapeutics to Present at William Blair Biotech Focus Conference
Jul 6, 2022 07:00AM Entrada Therapeutics to Present at William Blair Biotech Focus Conference
Jun 1, 2022 07:00AM Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
Jun 1, 2022 07:00AM Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
May 12, 2022 07:03AM Entrada Therapeutics (TRDA) Reports Q1 Net Loss of $21.7M
May 12, 2022 07:00AM Entrada Therapeutics Reports First Quarter 2022 Financial Results
May 12, 2022 07:00AM Entrada Therapeutics Reports First Quarter 2022 Financial Results
May 11, 2022 09:32AM Entrada Therapeutics (TRDA) Reports New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle Therapeutics
May 11, 2022 09:30AM Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
May 11, 2022 09:30AM Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
May 10, 2022 07:00AM Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 10, 2022 07:00AM Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
Mar 15, 2022 07:00AM Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 15, 2022 07:00AM Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 23, 2022 08:00AM Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
Feb 23, 2022 08:00AM Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
Jan 5, 2022 08:00AM Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
Jan 5, 2022 08:00AM Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
Dec 17, 2021 08:00AM Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
Dec 17, 2021 08:00AM Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes
Dec 9, 2021 07:06AM Entrada Therapeutics (TRDA) Reports Q3 Net Loss of $14.4M, Cash and Cash Equivalents of $122.2M
Dec 9, 2021 07:00AM Entrada Therapeutics Reports Third Quarter 2021 Financial Results
View More Recent Stories View Older Stories